http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Dong Ha Kim,HyeongRyul Kim,Yun Jung Choi,Seon Ye Kim,Jung Eun Lee,Ki Jung Sung,Young Hoon Sung,Chan-Gi Pack,Min Kyo Jung,Buhm Han,Kunhee Kim,Woo Sung Kim,Soo Jeong Nam,Chang Min Choi,Miyong Yun,Jae Ch 생화학분자생물학회 2019 Experimental and molecular medicine Vol.51 No.-
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarify predictive biomarkers for drug efficacy and to understand the fundamental mechanism of PD-1/PD-L1 interaction between host and tumor cells. Here, we show that exosomes derived from lung cancer cells express PD-L1 and play a role in immune escape by reducing T-cell activity and promoting tumor growth. The abundance of PD-L1 on exosomes represented the quantity of PD-L1 expression on cell surfaces. Exosomes containing PD-L1 inhibited interferon-gamma (IFN-γ) secretion by Jurkat T cells. IFN-γ secretion was restored by PD-L1 knockout or masking on the exosomes. Both forced expression of PD-L1 on cells without PD-L1 and treatment with exosomes containing PD-L1 enhanced tumor growth in vivo. PD-L1 was present on exosomes isolated from the plasma of patients with non-small cell lung cancer, and its abundance in exosomes was correlated with PD-L1 positivity in tumor tissues. Exosomes can impair immune functions by reducing cytokine production and inducing apoptosis in CD8+ T cells. Our findings indicate that tumor-derived exosomes expressing PD-L1 may be an important mediator of tumor immune escape.
Nam, Jutaek,La, Wan-Geun,Hwang, Sekyu,Ha, Yeong Su,Park, Nokyoung,Won, Nayoun,Jung, Sungwook,Bhang, Suk Ho,Ma, Yoon-Ji,Cho, Yong-Min,Jin, Min,Han, Jin,Shin, Jung-Youn,Wang, Eun Kyung,Kim, Sang Geol,Ch American Chemical Society 2013 ACS NANO Vol.7 No.4
<P>A challenge in using plasmonic nanostructure–drug conjugates for thermo–chemo combination cancer therapy lies in the huge size discrepancy; the size difference can critically differentiate their biodistributions and hamper the synergistic effect. Properly tuning the plasmonic wavelength for photothermal therapy typically results in the nanostructure size reaching ∼100 nm. We report a new combination cancer therapy platform that consists of relatively small 10 nm pH-responsive spherical gold nanoparticles and conjugated doxorubicins. They are designed to form aggregates in mild acidic environment such as in a tumor. The aggregates serve as a photothermal agent that can selectively exploit external light by their collective plasmon modes. Simultaneously, the conjugated doxorubicins are released. The spatiotemporal concertion is confirmed at the subcellular, cellular, and organ levels. Both agents colocalize in the cell nuclei. The conjugates accumulate in cancer cells by the rapid phagocytic actions and effective blockage of exocytosis by the increased aggregate size. They also effectively accumulate in tumors up to 17 times over the control because of the enhanced permeation and retention. The conjugates exhibit a synergistic effect enhanced by nearly an order of magnitude in cellular level. The synergistic effect is demonstrated by the remarkable reductions in both the therapeutically effective drug dosage and the photothermal laser threshold. Using an animal model, effective tumor growth suppression is demonstrated. The conjugates induce apoptosis to tumors without any noticeable damage to other organs. The synergistic effect <I>in vivo</I> is confirmed by qRT-PCR analysis over the thermal stress and drug-induced growth arrest.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/ancac3/2013/ancac3.2013.7.issue-4/nn400223a/production/images/medium/nn-2013-00223a_0008.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nn400223a'>ACS Electronic Supporting Info</A></P>
이영진(Young Jin Lee),한동화(DH Han),반충환(CH Ban),김영우,성백서,은종목(JM Eun),최규하(Gyu Ha Choe) 전력전자학회 2010 전력전자학술대회 논문집 Vol.2010 No.11
본 논문에서는 삼상 AC-DC 컨버터와 강압컨버터를 이용한 배터리 충전장치를 제안한다. 제안 하는 배터리 충전시스템은 상용전원뿐만 아니라 태양광시스템의 MPPT제어를 통하여 최대전력을 공급받아 급속충전시스템의 CV/CC(정전압/정전류)모드 제어를 통해 배터리를 빠르게 충전한다.
( Hyo Jeong Oh ),( Young Mi Mok ),( Moon Seong Ba다 ),( Bong Soo Seo ),( Tae Hyeon Kim ),( Keum Ha Choi ),( In Kyeom Hwang ),( Ji Eun Ra ),( Yong Reol Oh ),( Yong Sung Kim ),( Eun Young Cho ),( Haak Ch 대한간학회 2013 Clinical and Molecular Hepatology(대한간학회지) Vol.19 No.3
Autoimmune hepatitis (AIH) has been reported in association with Sjogren`s syndrome (55). Drug-induced AIH has been rarely reported. A rare case of the co-development of AIH and 55 in a 53-year-old woman after the consumption of herbal medicines is described. After admission, the patient complained of dryness in her mouth, and she was subsequently diagnosed with 55, which had not been detected previously. The patient`s bilirubin and aminotransferase levels initially decreased following conservative management; however, they later began to progressively increase. A diagnosis of AIH was made based on the scoring system proposed by the International Autoimmune Hepatitis Group. The patient was administered a combination of prednisolone and azathioprine, and the results of fOllow-up liver-function tests were found to be within the normal range. This is an unusual case of AIH and 55 triggered simultaneously by the administration of herbal medicines. ((Iin Mol HepatoI2013;19:30S-308)
The Diagnostic Efficacy of M2BPGi for Liver Fibrosis in HCC and NAFLD Patients
( Se Young Jang ),( Won Young Tak ),( Soo Young Park ),( Young-oh Kweon ),( Yu Rim Lee ),( Bina Jeong ),( Sangkyung Seo ),( Gyoun-eun Kang ),( Gyeonghwa Kim ),( Keun Hur ),( Heon Tak Ha ),( Jae Min Ch 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Mac-2 binding protein glycan isomer (M2BPGi) is recently identified as a useful non-invasive biomarker for the diagnosis of liver fibrosis. This study aimed to evaluate the diagnostic efficacy of serum M2BPGi for liver fibrosis in hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD) patients. Methods: M2BPGi levels were analyzed in serum samples collected from biopsy-proven HCC (n=135) and NAFLD (n=113) patients. Fibrosis was graded histopathologically in non-tumorous portion of HCC and NAFLD. Serum M2BPGi levels were determined with an automated immunoassay analyzer. Spearman’s correlation and Kruskal-Wallis test were used to evaluate the correlation and comparison among groups. Diagnostic efficacy for fibrosis was evaluated by the area under the receiver operating characteristic curve (AUC). Results: Median levels (range) of M2BPGi in HCC and NAFLD patients were 1.21 (0.12-14.33) cut-off index (COI) and 0.59 (0.13-5.90) COI, respectively. In HCC patients, fibrosis stages were 0 (n=22), 1 (n=10), 2 (n=11), 3 (n=16), and 4 (n=76). The M2BPGi levels showed a significant positive correlation (r= 0.436, P<0.001) with fibrosis grade in HCC patients and yielded the lower AUC value, 0.787 (P< 0.001) than transient elastography (TE), AUC value, 0.806 (P=0.030) to predict advanced fibrosis (F >2). In NAFLD patients, fibrosis stages were 0 (n=22), 1 (n=34), 2 (n=28), 3 (n=19), and 4 (n=10). The M2BPGi levels showed a significant positive correlation (r=0.578, P<0.001) with fibrosis grade in NAFLD patients and yielded the higher AUC value, 0.824(P< 0.001) than TE, AUC value, 0.637(P=0.035) to predict advanced fibrosis (F >2). Conclusions: Serum M2BPGi can be a useful non-invasive biomarker for predicting fibrosis in HCC and especially in NAFLD patients.